Moleculin Biotech Inc (MBRX)

[The_BORG]

NEW YORK, NY / ACCESSWIRE / July 12, 2017 / Therapeutics MD soared on Tuesday after an analyst gave an upbeat rating on the stock as well as a price tag more than 100% higher than current share prices. Moleculin Biotech also saw big gains despite any big news but the company has been releasing significant press releases in the last few weeks, including one that reveals the company has discovered a metabolic inhibitor with the potential to treat pancreatic cancer.

RDI Initiates Coverage on:

TherapeuticsMD, Inc.https://ub.rdinvesting.com/news/?ticker=TXMD

Moleculin Biotech, Inc.https://ub.rdinvesting.com/news/?ticker=MBRX

TherapeuticsMD, Inc.'s shares closed in the green up 3.96% yesterday. Shares were up as much as 18.75% when the stock hit $5.70 during intra-day trading. The big move came after traders found out that an analyst at Oppenheimer upgraded the stock from "perform" to "outperform." He also gave shares a $10 price target which would be a major increase from current share prices. Jay Olson of Oppenheimer believes that there could be positive news from TherapeuticsMD's meeting with the FDA on or around the 14th of this month. According to Oppenheimer, the company will likely resubmit TX-004HR by the 31st and there could be a possible FDA approval by September 29. Olson says the probability of this is 60%. TX-004HR was rejected by the FDA a few months back as there were concerns that there was a lack of long-term endometrial safety data. TX-004HR is an investigational applicator-free estradiol vaginal soft gel capsule that is intended to treat moderate-to-severe vaginal pain.

Access RDI'sTherapeuticsMD, Inc. Research Report at: https://ub.rdinvesting.com/news/?ticker=TXMD

Moleculin Biotech, Inc.'s shares closed up 8.45% on Tuesday despite any remarkable news. It was earlier this month however that the preclinical pharma company announced that it has appointed Dr. Lidia Gil from Poznan University of Medical Sciences in Poland to be the leader of its European Principal Investigator (PI) for the planned Phase I/II clinical trial of Annamycin. Annamycin is an anthracycline that is being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. CEO Walter Klemp commented, "Dr. Gil is a highly-respected hematologist-oncologist in Poland and we are honored to have her leading the European element of our upcoming clinical trial for Annamycin, which would commence only if our IND is permitted."

Dr. Gil Commented, "We are so pleased to be hosting the planned Annamycin clinical trial here in Poland. The absence of an approved second-line therapy for relapsed or refractory AML patients represents a significant unmet need and demonstrating activity in this trial could represent a major development in the treatment of AML."

It was also last month that the company announced that it has discovered a metabolic inhibitor with the potential to treat pancreatic cancer.

Access RDI'sMoleculin Biotech, Inc. Research Report at: https://ub.rdinvesting.com/news/?ticker=MBRX

Our Actionable Research on TherapeuticsMD, Inc. (NYSE:TXMD) and Moleculin Biotech, Inc. (NASDAQ:MBRX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

[e-mail]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE:RDInvesting.com



This article appears in: News Headlines

Referenced Stocks: MBRX, TXMD